Wegovy is administered once weekly on the same day each week through subcutaneous injection into the thigh, abdomen, or upper arm, with sites rotated to prevent skin irritation. Proper injection ...

Cosentyx (secukinumab) comes as a subcutaneous injection under the skin or an intravenous (IV) infusion into a vein. Doctors may prescribe it to treat plaque psoriasis, psoriatic arthritis, and other ...

This newer mode of administration for immunotherapy comes with benefits and risks. It is important for a person to work with a doctor when making treatment decisions for upper gastrointestinal (GI) ...

Roche Pharma India has launched a subcutaneous Tecentriq injection for eligible lung cancer patients. The shorter dosing time ...

Please provide your email address to receive an email when new articles are posted on . Leqembi Iqlik is the first approved in-home anti-amyloid injectable for early Alzheimer’s disease. Patients ...

Immunotherapy, exemplified by Opdivo, enhances cancer treatment by targeting malignant cells using the immune system, offering a more precise approach than traditional therapies. The FDA approved ...

For individuals living with cancer, navigating treatment can be a significant challenge, often requiring substantial time commitments and disruptions to daily life. Traditionally, immunotherapy ...

Korea approves Keytruda SC, slashing treatment time to 2 minutes Alteogens ALT-B4 enables faster subcutaneous Keytruda launch ...

On December 22, 2025, the U.S. Food and Drug Administration (FDA) approved an oral pill form of Wegovy — a glucagon-like peptide-1 (GLP-1) receptor agonist medication for weight loss. Until now, ...

The US Food and Drug Administration (FDA) has approved the biologics license application for a subcutaneous formulation of lecanemab (Leqembi Iqlik) for weekly maintenance dosing to treat Alzheimer’s ...

MILAN -- An investigational 10-minute subcutaneous injection of ocrelizumab (Ocrevus) was non-inferior to the established IV infusion formulation of the drug in multiple sclerosis (MS), the phase III ...

FDA’s three-month extension was triggered by a major amendment after the agency requested additional information during priority review, necessitating more time to evaluate newly submitted materials.